What type of study is this?

Camrelizumab and Chemotherapy as Neoadjuvant Treatment for Locallyadvanced Esophageal Squamous Cell Carcinoma (Escc)a Single-Arm, Phase Ii Trial

View Full Paper

Ask AI

Bookmark

Neoadjuvant treatment achieved a major pathological response rate of 67.6% in patients with ESCC.
Of 34 patients completing treatment, 17.6% had a pathological complete response, indicating efficacy in this population.
Analysis revealed that infiltrated lymphocyte levels were significantly lower in non-responders, affecting treatment outcomes.
Findings indicate that myeloid-derived suppressor cells may play a role in poor immunotherapy responses in ESCC.

No takes yet. Share an insight, caveat, or question.

Phase II trial shows significant major pathological response in patients with advanced ESCC, suggesting immunotherapy's potential impact.

Tang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark